General MedicationsINTRAVENOUSStandard
SIVEXTRO
TEDIZOLID PHOSPHATE
Standard Dose
200MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SIVEXTRO is listed in Drugs@FDA under application 205436 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TEDIZOLID PHOSPHATE Form and strength POWDER;INTRAVENOUS - 200MG/VIAL Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2026-02-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview SIVEXTRO is listed in Drugs@FDA under application 205436 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TEDIZOLID PHOSPHATE Form and strength POWDER;INTRAVENOUS - 200MG/VIAL Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2026-02-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.